Amgen Inc.
Amgen Inc. (NASDAQ: AMGN) is a biotechnology business focused on assisting people with serious illnesses. The company creates, manufactures, and sells a wide range of human treatments. It has grown into one of the world's most successful independent biotechnology companies, reaching millions of patients globally and developing a pipeline of potentially game-changing drugs. Its most well-known medications are ENBREL, Prolia, Otezla, XGEVA, Neulasta, Aranesp, Repatha, and KYPROLIS.
Why Should Investors Book Profit?
- Weak Liquidity Profile: The company's current ratio at the end of FY21 is 1.59x, compared to the industry median of 6.15x. This implies relatively lackluster liquidity profile against the industry median.
- High Cash Conversion Days: Compared to the industry, the company has a long Cash Conversion Cycle (Days), meaning that it takes more days to convert its sales to cash. As of FY21, its Cash Cycle was 226 days, compared to an industry median of 66 days.
- Manufacturing Facility Concentration Risk: AMGN's manufacturing facilities continued and efficient operation, particularly in the US territories of Puerto Rico and Thousand Oaks, California, is critical to the global supply of product candidates for commercial sales and clinical trials. A significant disruption in the company's ability to operate its manufacturing facilities could jeopardise its ability to supply product candidates for clinical trials, causing delays in product development.
- Technical Weakness: AMGN’s prices moved up by 16.90% from the recommended entry price and made a high of USD 251.46 on April 06, 2022. Price reached a crucial resistance level of USD 252 but were unable to break this level, indicating the possibility of a downside correction which may lead the prices towards the resistance turned support level USD 239.On the daily chart, RSI (14-period) is reached an overbought zone at 81.93 levels, supporting a downside correction. However, prices are still sustaining above the trend-following indicators 21-period SMA and 50-period SMA and may act as the support levels for the stock.
Valuation Methodology: Price/Earnings Per Share Multiple Based Relative Valuations
(Analysis by Kalkine Group)
* % Premium/(Discount) is based on our assessment of the company's FY1 trading multiple after considering its key growth drivers, economic moat, stock's historical trading multiples versus peer average/median, and investment risks.
Stock Recommendation:
AMGN's share price has inclined 19.74% in the past six months and is currently leaning towards the higher band of the 52-week range of USD 198.64 to USD 261. We have valued the stock using the Price/Earnings-based relative valuation methodology and arrived at a target price of USD 220.88.
Considering the company's long cash cycle, weak liquidity profile, current valuation, and associated risks. We recommend a "Sell" rating on the stock at the current price of USD 254.65, up 1.03% as of April 11, 2022, at 09:01 AM PDT.
1-Year Technical Price Chart (as of April 11, 2022, at 09:01 AM PDT). Source: REFINITIV, Analysis by Kalkine Group
* The reference data in this report has been partly sourced from REFINITIV.
* All forecasted figures and industry information have been taken from REFINITIV.
Disclaimer - This report has been issued by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and prepared by Kalkine and its related bodies corporate authorised to provide general financial product advice. Kalkine.com.au and associated pages are published by Kalkine.
Any advice provided in this report is general advice only and does not take into account your objectives, financial situation or needs. You should therefore consider whether the advice is appropriate to your objectives, financial situation and needs before acting upon it.
There may be a Product Disclosure Statement, Information Statement or other offer document for the securities or other financial products referred to in Kalkine reports. You should obtain a copy of the relevant Product Disclosure Statement, Information Statement or offer document and consider the statement or document before making any decision about whether to acquire the security or product.
You should also seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) as necessary before acting on any advice in this report or on the Kalkine website. Not all investments are appropriate for all people.
The information in this report and on the Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of information contained in its reports, newsletters and websites. All information represents our views at the date of publication and may change without notice.
Kalkine does not guarantee the performance of, or returns on, any investment. To the extent permitted by law, Kalkine excludes all liability for any loss or damage arising from the use of this report, the Kalkine website and any information published on the Kalkine website (including any indirect or consequential loss, any data loss or data corruption). If the law prohibits this exclusion, Kalkine hereby limits its liability, to the extent permitted by law, to the resupply of services.
Please also read our Terms & Conditions and Financial Services Guide for further information.
On the date of publishing this report (referred to on the Kalkine website), employees and/or associates of Kalkine and its related entities do not hold interests in any of the securities or other financial products covered on the Kalkine website unless those persons comply with certain safeguards, procedures, and disclosures.
Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.